Clinical Trials

{
  "url": "https://clinicaltrials.gov/study/NCT05318521",
  "title": "RCT, Blinded, 2-Arm Efficacy Study of IP and Placebo in Patients With Chronic Pain Related to Osteoarthritis of the Knee",
  "nct_id": "NCT05318521",
  "phases": [
    "PHASE3"
  ],
  "source": "clinicaltrials.gov",
  "status": "ACTIVE_NOT_RECRUITING",
  "conditions": [
    "Degenerative Arthritis"
  ],
  "enrollment": 500,
  "study_type": "INTERVENTIONAL",
  "lead_sponsor": "Overseas Pharmaceuticals, Ltd.",
  "published_at": "2026-07-27T00:00:00.000Z",
  "interventions": [
    {
      "name": "Placebo",
      "type": "DRUG"
    },
    {
      "name": "Ibuprofen modified release tablet 800 mg",
      "type": "DRUG"
    }
  ],
  "sponsor_class": "INDUSTRY",
  "official_title": "A Randomized, Double-Blind, Parallel-Arm Study Comparing the Efficacy of Investigational Product \"Ibuprofen Modified-Release Tablets 800 mg\" and Placebo in Patients With Chronic Pain Related to Osteoarthritis of the Knee",
  "first_posted_at": "2022-04-08T00:00:00.000Z"
}

{
  "url": "https://clinicaltrials.gov/study/NCT06931821",
  "title": "Functional ElectroAnatomiC Isochronal Late Activation Mapping for Empiric VT Ablation Trial",
  "nct_id": "NCT06931821",
  "phases": [
    "NA"
  ],
  "source": "clinicaltrials.gov",
  "status": "RECRUITING",
  "conditions": [
    "Sustained Monomorphic VT (MMVT)",
    "Recurrent Ventricular Tachycardia"
  ],
  "enrollment": 360,
  "study_type": "INTERVENTIONAL",
  "lead_sponsor": "University of Arizona",
  "published_at": "2026-07-27T00:00:00.000Z",
  "interventions": [
    {
      "name": "Isochronal Late Activation Mapping (ILAM)",
      "type": "DEVICE"
    },
    {
      "name": "High Density Voltage Mapping",
      "type": "DEVICE"
    }
  ],
  "sponsor_class": "OTHER",
  "official_title": "Functional ElectroAnatomiC Isochronal Late Activation Mapping for Empiric VT Ablation Trial",
  "first_posted_at": "2025-04-17T00:00:00.000Z"
}

{
  "url": "https://clinicaltrials.gov/study/NCT04012944",
  "title": "SIRONA 2 Trial Heart Failure NYHA Class III",
  "nct_id": "NCT04012944",
  "phases": [
    "NA"
  ],
  "source": "clinicaltrials.gov",
  "status": "ACTIVE_NOT_RECRUITING",
  "conditions": [
    "Heart Failure NYHA Class III"
  ],
  "enrollment": 81,
  "study_type": "INTERVENTIONAL",
  "lead_sponsor": "Endotronix, Inc.",
  "published_at": "2026-07-27T00:00:00.000Z",
  "interventions": [
    {
      "name": "Cordella™ Pulmonary Artery Sensor System",
      "type": "DEVICE"
    }
  ],
  "sponsor_class": "INDUSTRY",
  "official_title": "A Prospective, Multi-Center, Open-Label, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Pulmonary Artery Sensor System in New York Heart Association (NYHA) Class III Heart Failure Patients (SIRONA 2 Trial)",
  "first_posted_at": "2019-07-09T00:00:00.000Z"
}

{
  "url": "https://clinicaltrials.gov/study/NCT07363694",
  "title": "A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease",
  "nct_id": "NCT07363694",
  "phases": [
    "PHASE2",
    "PHASE3"
  ],
  "source": "clinicaltrials.gov",
  "status": "RECRUITING",
  "conditions": [
    "Moderate to Severe Chronic Obstructive Pulmonary Disease"
  ],
  "enrollment": 1156,
  "study_type": "INTERVENTIONAL",
  "lead_sponsor": "Pfizer",
  "published_at": "2026-07-27T00:00:00.000Z",
  "interventions": [
    {
      "name": "PF-07275315 dose 1",
      "type": "DRUG"
    },
    {
      "name": "PF-07275315-dose 2",
      "type": "DRUG"
    },
    {
      "name": "Placebo",
      "type": "DRUG"
    },
    {
      "name": "PF-07275315-dose 3",
      "type": "DRUG"
    }
  ],
  "sponsor_class": "INDUSTRY",
  "official_title": "AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)",
  "first_posted_at": "2026-01-23T00:00:00.000Z"
}

{
  "url": "https://clinicaltrials.gov/study/NCT07416188",
  "title": "Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma",
  "nct_id": "NCT07416188",
  "phases": [
    "PHASE1",
    "PHASE2"
  ],
  "source": "clinicaltrials.gov",
  "status": "RECRUITING",
  "conditions": [
    "Recurrent Glioblastoma",
    "Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype",
    "Relapsed Cancer",
    "Recurrent Tumor",
    "Glioblastoma Multiforme",
    "Recurring Glioblastoma",
    "Brain and Central Nervous System Tumors",
    "Glioma",
    "Glioblastomas",
    "Grade IV Astrocytoma"
  ],
  "enrollment": 40,
  "study_type": "INTERVENTIONAL",
  "lead_sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
  "published_at": "2026-07-27T00:00:00.000Z",
  "interventions": [
    {
      "name": "LMP744",
      "type": "DRUG"
    },
    {
      "name": "Conventional Surgery or Biopsy",
      "type": "PROCEDURE"
    }
  ],
  "sponsor_class": "NIH",
  "official_title": "Phase 1/Phase 2 Open Label Trial of a Novel Indenoisoquinolone C-MYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma",
  "first_posted_at": "2026-02-18T00:00:00.000Z"
}

{
  "url": "https://clinicaltrials.gov/study/NCT07619534",
  "title": "Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases",
  "nct_id": "NCT07619534",
  "phases": [],
  "source": "clinicaltrials.gov",
  "status": "NOT_YET_RECRUITING",
  "conditions": [
    "Breast Cancer",
    "Breast Carcinoma",
    "Cancer of the Breast",
    "Malignant Neoplasm of Breast"
  ],
  "enrollment": 139,
  "study_type": "OBSERVATIONAL",
  "lead_sponsor": "National Cancer Institute (NCI)",
  "published_at": "2026-07-27T00:00:00.000Z",
  "interventions": [
    {
      "name": "Arm 1",
      "type": "OTHER"
    }
  ],
  "sponsor_class": "NIH",
  "official_title": "Sample Collection Study to Analyze Cerebral Spinal Fluid as a Biomarker for Brain Metastasis in Metastatic Breast Cancer",
  "first_posted_at": "2026-06-02T00:00:00.000Z"
}

{
  "url": "https://clinicaltrials.gov/study/NCT04798469",
  "title": "Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism",
  "nct_id": "NCT04798469",
  "phases": [
    "PHASE2"
  ],
  "source": "clinicaltrials.gov",
  "status": "RECRUITING",
  "conditions": [
    "Opioid Use",
    "Pain",
    "Hypogonadism, Male"
  ],
  "enrollment": 150,
  "study_type": "INTERVENTIONAL",
  "lead_sponsor": "Brigham and Women's Hospital",
  "published_at": "2026-07-27T00:00:00.000Z",
  "interventions": [
    {
      "name": "Testosterone Undecanoate 250 MG/ML",
      "type": "DRUG"
    },
    {
      "name": "Placebo",
      "type": "DRUG"
    }
  ],
  "sponsor_class": "OTHER",
  "official_title": "Androgen Replacement to Improve Patient-Important Outcomes in Men With Opioid-Induced Hypogonadism",
  "first_posted_at": "2021-03-15T00:00:00.000Z"
}

{
  "url": "https://clinicaltrials.gov/study/NCT06388642",
  "title": "Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients",
  "nct_id": "NCT06388642",
  "phases": [
    "PHASE1",
    "PHASE2"
  ],
  "source": "clinicaltrials.gov",
  "status": "COMPLETED",
  "conditions": [
    "Erythropoietic Protoporphyria"
  ],
  "enrollment": 28,
  "study_type": "INTERVENTIONAL",
  "lead_sponsor": "Clinuvel Europe Limited",
  "published_at": "2026-07-27T00:00:00.000Z",
  "interventions": [
    {
      "name": "Afamelanotide 16mg implant",
      "type": "DRUG"
    }
  ],
  "sponsor_class": "INDUSTRY",
  "official_title": "A Study to Evaluate the Pharmacokinetics of Afamelanotide in Patients With Erythropoietic Protoporphyria (EPP)",
  "first_posted_at": "2024-04-29T00:00:00.000Z"
}

{
  "url": "https://clinicaltrials.gov/study/NCT06395103",
  "title": "Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)",
  "nct_id": "NCT06395103",
  "phases": [
    "PHASE1",
    "PHASE2"
  ],
  "source": "clinicaltrials.gov",
  "status": "RECRUITING",
  "conditions": [
    "B-cell Acute Lymphoblastic Leukemia",
    "Diffuse Large B-cell Lymphoma",
    "Burkitt Lymphoma",
    "Neuroblastoma",
    "Ewing Sarcoma"
  ],
  "enrollment": 90,
  "study_type": "INTERVENTIONAL",
  "lead_sponsor": "Merck Sharp & Dohme LLC",
  "published_at": "2026-07-27T00:00:00.000Z",
  "interventions": [
    {
      "name": "Zilovertamab vedotin",
      "type": "BIOLOGICAL"
    }
  ],
  "sponsor_class": "INDUSTRY",
  "official_title": "LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors",
  "first_posted_at": "2024-05-01T00:00:00.000Z"
}

{
  "url": "https://clinicaltrials.gov/study/NCT07706686",
  "title": "Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection",
  "nct_id": "NCT07706686",
  "phases": [
    "PHASE1"
  ],
  "source": "clinicaltrials.gov",
  "status": "RECRUITING",
  "conditions": [
    "Healthy Volunteers",
    "Dengue",
    "Human Challenge Trial"
  ],
  "enrollment": 200,
  "study_type": "INTERVENTIONAL",
  "lead_sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
  "published_at": "2026-07-27T00:00:00.000Z",
  "interventions": [
    {
      "name": "rDEN2delta30-7169",
      "type": "BIOLOGICAL"
    }
  ],
  "sponsor_class": "NIH",
  "official_title": "Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection",
  "first_posted_at": "2026-07-16T00:00:00.000Z"
}